Contact your healthcare provider promptly (within 1-2 days) if you develop: Persistent or worsening injection site reactions that do not resolve within a few days, show signs of infection (increasing warmth, spreading redness, purulent drainage, fever), or significantly interfere with your ability to continue injections New or changing skin lesions , particularly moles or spots that are asymmetric, have irregular borders, show color variation, are larger than 6mm in diameter, or are evolving in appearance (following the ABCDE criteria for melanoma screening) Unexplained rash or skin discoloration that persists for more than a few days or is accompanied by systemic symptoms such as fever, joint pain, or malaise Severe or progressive hair loss that causes significant distress or appears disproportionate to the degree of weight loss Signs of skin infection , including cellulitis, abscess formation, or spreading erythema, particularly if you have poorly controlled blood glucose, which increases infection risk and impairs wound healing [17] [18] Your healthcare provider can assess whether skin changes are related to tirzepatide therapy, associated with weight loss, or represent an independent dermatologic condition requiring specific treatment
Tesamorelin holds FDA approval for HIV-associated lipodystrophy and carries the strongest regulatory standing in this category
It helps researchers ask more nuanced questions about how different pathways interact to regulate the body's energy balance
The honest assessment is that individual ingredients have documented biological roles, but no large-scale randomized controlled trial has tested the combined injectable formulation for weight loss
Orforglipron met superiority criteria across the primary and all key secondary endpoints, including significantly higher proportions of patients achieving stringent A1C targets
